Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00162
2008-05-07
Prospective
nil
nil
nil
nil
Lee Chui Ping
622B, Li Choh Ming BMSB, The Chinese University of HK
26096819
cplee@cuhk.edu.hk cplee@cuhk.edu.hk
School of Pharmacy, CUHK
Lee Chui Ping
622B, Li Choh Ming BMSB, The Chinese University of HK
26096819
cplee@cuhk.edu.hk cplee@cuhk.edu.hk
School of Pharmacy, CUHK
Use of niacin for erectile dysfunction in patients with concomitant hyperlipidaemia
Use of niacin for erectile dysfunction in patients with concomitant hyperlipidaemia
Use of niacin for erectile dysfunction in patients with concomitant hyperlipidaemia
Hong Kong, China
Yes
2007-08-07
erectile dysfunction
Drug
niacin
12 wks
placebo
Subjects who are male older than or equal to 18 years old and in a steady relationship with the same female partner for more than 6 months, with a documented history of hyperlipidaemia and ED (defined as a consistent change in the quality of erection that adversely affects the subject's satisfaction with sexual intercourse) of any severity or aetiology (i.e. psychogenic, organic, or mixed) may be included. Subjects with history of PDE 5-inhibitor use can be included in the study as long as they are willing to undergo a 2-week washout period. They could not use any other form of ED treatment for the duration of the study.
Exclusion criteria Subjects with untreated endocrine disease (e.g. hypogonadism); a history of radical prostatectomy (except nerve-sparing with residual erectile function) or other pelvic surgery; clinically significant penile deformity; a history of penile implant; significant renal (sCr> 150 micromol/L) or liver disease (AST/ALT > 3 times upper limit of normal); a haemoglobin A1C of >13% should be excluded from the study. Patients who take aspirin or NSAIDs on a regular basis will also be excluded from the study.
18
80
Male
Interventional
Randomized
Placebo
Double-blind
Parallel
2008-05-14
157
Complete
The primary outcome measurements will be questions 3 (frequency of penetration) and 4 (frequency of maintained erections after penetration) of the International Index of Erectile Function (IIEF).
Secondary outcome measurements include the 5 functional domains of the IIEF, the Life Satisfaction Checklist,13 and change in lipid panels.
2011-04-13
ChiCTR-TRC-09000722
2010-05-04
|
|
|
|
---|---|---|---|
No documents yet. |